Aurinia Pharmaceuticals to Participate in Upcoming Conferences
January 26 2017 - 4:05PM
Business Wire
- Canaccord Genuity Rare Disease Biopharma 1x1
Day on February 7 in New York City
-Leerink Partners 6th Annual Global Healthcare
Conference on February 16 in New York City
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today
announced that Michael Martin, Chief Operating Officer, and Celia
Economides, Associate VP of Investor Relations, will participate in
the Canaccord Genuity Rare Disease Biopharma 1x1 Day on February
7th in New York City and the Leerink Partners 6th Annual Global
Healthcare Conference on February 16th at 11:30am ET. A webcast
will be available for the Leerink Conference and can be accessed
via the investor section of the Aurinia website,
www.auriniapharma.com. A replay will also be archived on the site
following the event.
About AuriniaAurinia is a clinical stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations that are suffering
from serious diseases with a high unmet medical need. The company
is currently developing voclosporin, an investigational drug, for
the treatment of lupus nephritis (LN), an inflammation of the
kidney caused by Systemic Lupus Erythematosus (SLE) and represents
a serious progression of SLE. The company is headquartered in
Victoria, BC and focuses its development efforts globally.
www.auriniapharma.com.
We Seek Safe Harbor.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170126006188/en/
Aurinia Pharmaceuticals Inc.Investor & Media
Contact:Celia EconomidesHead of IR &
Communicationsceconomides@auriniapharma.com